Combination Therapy Benefits Patients with Acute Myeloid Leukemia

Share this content:
Combination therapy benefits patients with acute myeloid leukemia
Combination therapy benefits patients with acute myeloid leukemia
Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin. The current accepted treatment, cytarabine, when used with other existing agents such as anthracyclines, is associated with increased toxic side effects.
READ FULL ARTICLE From News Medical
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters